TH-302 (Evofosfamide) (NCT02076230) targets hypoxic tumor cells and PX-478 (NCT00522652) acts by inhibiting hypoxia-inducible factor-1 alpha (HIF-1α). (Tao et al., 2021; Kao et al., 2023). This evidence concerns the gene HIF1A and neoplasm.